Anzeige
Mehr »
Login
Dienstag, 19.03.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Der Zug verlässt den Bahnhof - Umringt von potenziellen Käufern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14SVV | ISIN: FR0012596468 | Ticker-Symbol: RFM
Frankfurt
18.03.24
16:18 Uhr
0,910 Euro
+0,058
+6,81 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SENSORION SA Chart 1 Jahr
5-Tage-Chart
SENSORION SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,8270,88618.03.

Aktuelle News zur SENSORION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrSensorion Announces its Participation in the Annual Bioprocessing Summit Europe164Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
DoSensorion reports FY results1
DoSensorion Announces the Availability of its Financial Report for 2023244Regulatory News: Sensorion (FR0012596468 ALSEN) (Paris:ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and...
► Artikel lesen
DoSensorion Reports Full-Year 2023 Financial Results and Business Update251Milestone achieved for SENS-501 gene therapy program with Clinical Trial Application approval in Europe (France as first country) Communication on first patient expected in H2 2024...
► Artikel lesen
11.03.Sensorion's hearing loss drug reaches target in comeback story after phase 2 failure1
11.03.Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation171Presence of SENS-401 in the perilymph is confirmed in 100% of the patients sampled following cochlear implantation at levels compatible with potential therapeutic efficacy Regulatory News: ...
► Artikel lesen
06.03.Sensorion Will Host a Webcast on March 14, 2024, to Announce its 2023 Annual Financial Results258Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
29.02.Sensorion Announces its Participation in the Leerink Partners Global Biopharma Conference221Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
09.02.Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors498Support from existing investors Redmile Group, Invus and Sofinnova Partners Participation from leading US Healthcare Specialists funds including Aquilo Capital, as well as two large investment...
► Artikel lesen
01.02.Sensorion completes Phase 2a trial enrollment for hearing loss drug2
01.02.Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation291Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
29.01.Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 47th Annual Midwinter Meeting236Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
25.01.Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director to the Board of Directors247Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
24.01.Sensorion Announces Amended Terms for the Warrants Issued in Connection With the Private Placement Completed in August 2023352The maturity of the warrant subscribed by Redmile in August 2023 will be postponed until December 31, 2033, with €1,6m additional prefunding to Sensorion Redmile's shareholding of 24,8%...
► Artikel lesen
19.01.Sensorion advances with gene therapy trial in France1
19.01.Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1/2 Clinical Trial in some European Countries320Sensorion has received approval to initiate Phase 1/2 clinical trial of SENS-501 (OTOF-GT) in France as first country SENS-501 is Sensorion's lead gene therapy candidate. It aims at restoring...
► Artikel lesen
05.01.Sensorion Announces Partnership With the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders Has Been Extended for Five Years409The framework extension agreement underlines the successful collaboration between Sensorion and the Institut Pasteur, involving the Hearing Institute, a research center of the Institut Pasteur...
► Artikel lesen
21.12.23Sensorion Publishes Results of Combined General Meeting Resolutions236Regulatory News: Sensorion (FR0012596468 ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent...
► Artikel lesen
18.12.23Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)230Preliminary data demonstrate that SENS-401 has a favorable safety profile when administered continuously for up to 11 weeks in adult patients undergoing cisplatin-based chemotherapy Recruitment...
► Artikel lesen
12.12.23Sensorion Appoints CMC Expert Bernd Schmidt as New Chief Technical Officer371Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
Seite:  Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1